Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate)

The active ingredients in Delstrigo are: doravine (a non-nucleoside reverse transcriptase inhibitor), lamivudine (a nucleoside analogue reverse transcriptase inhibitor), and tenofovir disoproxil fumarate (a nucleoside analogue reverse transcriptase inhibitor).

WARNING: POSTTREATMENT ACUTE EXACERBATION OF HEPATITIS B See full prescribing information for complete boxed warning. Severe acute exacerbations of hepatitis B (HBV) have been reported in patients coinfected with HIV-1 and HBV who have discontinued lamivudine or tenofovir disoproxil fumarate (TDF), two of the components of DELSTRIGO. Closely monitor hepatic function in these patients. If appropriate, initiation of anti-hepatitis B therapy may be warranted. Before you start taking Delstrigo, tell your doctor:, About any medications you take, including prescription, over-the-counter, vitamins, and herbal supplements., About all your health conditions, including hepatitis B infection, kidney problems, or bone problems, If you are pregnant or plan to become pregnant, If you are breastfeeding or plan to breastfeed, Delstrigo can cause immune system changes such as fighting off infections that have been dormant in your body. Contact your doctor right away if you develop new symptoms while being treated with Delstrigo. About any medications you take, including prescription, over-the-counter, vitamins, and herbal supplements., About all your health conditions, including hepatitis B infection, kidney problems, or bone problems, If you are pregnant or plan to become pregnant, If you are breastfeeding or plan to breastfeed

Delstrigo can cause side effects. The most common include unusual dreams, dizziness, and nausea. Tell your doctor if you develop side effects that bother you or won't go away.